These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 8195028

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC, Stratford IJ, Bowler J, Adams GE.
    Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
    [Abstract] [Full Text] [Related]

  • 3. Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
    Bremner JC, Adams GE, Pearson JK, Sansom JM, Stratford IJ, Bedwell J, Bown SG, MacRobert AJ, Phillips D.
    Br J Cancer; 1992 Dec; 66(6):1070-6. PubMed ID: 1457346
    [Abstract] [Full Text] [Related]

  • 4. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
    Bremner JC.
    Cancer Metastasis Rev; 1993 Jun; 12(2):177-93. PubMed ID: 8375020
    [Abstract] [Full Text] [Related]

  • 5. Interaction of the bioreductive drug SR 4233 and photodynamic therapy using photofrin in a mouse tumor model.
    Baas P, Oppelaar H, Stavenuiter M, van Zandwijk N, Stewart FA.
    Int J Radiat Oncol Biol Phys; 1993 Oct 20; 27(3):665-70. PubMed ID: 8226162
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour.
    Wood PJ, Horsman MR, Khalil AA, Steinberg F, Streffer C, Overgaard J, Stratford IJ, Adams GE.
    Acta Oncol; 1996 Oct 20; 35(8):989-94. PubMed ID: 9023383
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW.
    Br J Cancer; 1982 Feb 20; 45(2):272-81. PubMed ID: 6460517
    [Abstract] [Full Text] [Related]

  • 11. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct 20; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 12. Chemosensitization of lomustine by misonidazole, benznidazole, and RSU 1069.
    Workman P.
    Cancer Treat Rep; 1986 Sep 20; 70(9):1139-40. PubMed ID: 3755651
    [No Abstract] [Full Text] [Related]

  • 13. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J.
    Int J Radiat Oncol Biol Phys; 1992 Sep 20; 22(3):545-8. PubMed ID: 1735694
    [Abstract] [Full Text] [Related]

  • 14. Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.
    Twentyman P, Workman P.
    Br J Cancer; 1982 Mar 20; 45(3):447-55. PubMed ID: 7073938
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.
    Tannock IF.
    Br J Cancer; 1980 Dec 20; 42(6):871-80. PubMed ID: 7459221
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.